(Reuters) -The U.S. Centers for Disease Control and Prevention panel of vaccine experts will vote on shots for respiratory ...

GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

A U.S. government scientist who oversees the team responsible for collecting data on COVID-19 and RSV hospitalizations used ...

A Centers for Disease Control and Prevention official who led the agency's network to study hospitalization trends from ...

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

Tourists in Israel and Lebanon have found themselves stranded at airports amid Israel's conflict with Iran. Fiona Jones ...

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

Cleveland health officials are warning residents after a 250% spike in COVID-19 viral levels was found in city wastewater.

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on ...